Natural aging and HIV infection are associated with chronic low-grade systemic inflammation, immune senescence, and impaired antibody responses to vaccines such as the influenza (flu) vaccine. We investigated the role of IL-21, a CD4+ T follicular helper cell (Tfh) regulator, on flu vaccine antibody response in nonhuman primates (NHPs) in the context of age and controlled SIV mac239 infection. Three doses of the flu vaccine with or without IL-21-IgFc were administered at 3-month intervals in aged SIV+ NHPs following virus suppression with antiretroviral therapy. IL-21-treated animals demonstrated higher day 14-postboost antibody responses, which associated with expanded CD4+ T central memory cells and peripheral Tfh-expressing (pTfh-expressing) T cell immunoreceptor with Ig and ITIM domains (TIGIT), expanded activated memory B cells, and contracted CD11b+ monocytes. Draining lymph node (LN) tissue from IL-21-treated animals revealed direct association between LN follicle Tfh density and frequency of circulating TIGIT+ pTfh cells. We conclude that IL-21 enhances flu vaccine-induced antibody responses in SIV+ aged rhesus macaques (RMs), acting as an adjuvant modulating LN germinal center activity. A strategy to supplement IL-21 in aging could be a valuable addition in the toolbox for improving vaccine responses in an aging HIV+ population.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564910PMC
http://dx.doi.org/10.1172/jci.insight.150888DOI Listing

Publication Analysis

Top Keywords

antibody responses
12
flu vaccine
12
il-21 enhances
8
vaccine responses
8
il-21-treated animals
8
memory cells
8
vaccine
5
responses
5
il-21
4
enhances influenza
4

Similar Publications

Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) progressing after chimeric antigen receptor T-cell therapy (CAR T) have dismal outcomes. The prespecified post-CAR T expansion cohort of the ELM-1 study investigated the efficacy and safety of odronextamab, a CD20×CD3 bispecific antibody, in patients with disease progression after CAR T. Sixty patients received IV odronextamab weekly for 4 cycles followed by maintenance until progression.

View Article and Find Full Text PDF

Background: This research introduces a novel method for quantifying aggregated tau in body fluids, specifically cerebrospinal fluid (CSF), aiming to enhance the diagnosis and monitoring of neurodegenerative diseases, with a focus on Alzheimer's disease (AD).

Method: By combining tau protein amplification with a highly sensitive single-molecule array (Simoa) immunoassay using an anti-tau antibody CT19.1 in a homogenous manner, the approach enables precise measurements of tau aggregates in CSF.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Vaccinex, Inc., Rochester, NY, USA.

Background: The earliest recognized biomarker of AD is deposition of Aβ amyloid that leads to formation of plaques and may, over time, trigger or at least be followed by gliosis/neuroinflammation and neurofibrillary tangles, accompanied by neurodegenerative changes including neuronal and synaptic loss. We have previously reported that semaphorin 4D (SEMA4D), the major ligand of plexin B receptors expressed on astrocytes, is upregulated in diseased neurons during progression of AD and Huntington's disease (HD). Binding of SEMA4D to PLXNB receptors triggers astrocyte reactivity, leading to loss of neuroprotective homeostatic functions, including downregulation of glutamate and glucose transporters (doi:10.

View Article and Find Full Text PDF

Background: Analysis of neuroimaging data based on convolutional neural networks (CNNs) can improve detection of clinically relevant characteristics of patients with Alzheimer's disease (AD). Previously, our group developed a CNN-based approach for detecting AD via magnetic resonance imaging (MRI) scans and for identifying features that are relevant to the decision of the network. In the current study, we aimed to evaluate the potential utility of applying this approach to MRI scans to assist in the identification of individuals at high risk for amyloid positivity to aid in the selection of study samples and case finding for treatment.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

University of Minnesota, Minneapolis, MN, USA.

Background: A current hypothesis of the etiology of Alzheimer's disease (AD) suggests that soluble amyloid-ß (Aß) oligomers (Aßo) play a more significant role than amyloid plaques. Among the numerous Aßo discovered in the brain, Aß*56 has been shown to be associated with aging and cognitive dysfunction in mice, dogs, and humans, and impair memory in rodents. Evidence from our recent study indicates that Aß*56 produced from Tg2576 mice modeling AD is a ∼56-kDa, SDS-stable, A11 (anti-amyloid oligomer antibody)-reactive, water-soluble oligomer that impairs memory in healthy wild-type mice; and that there exist at least two Aß*56 variants-Aß(40)*56 and Aß(42)*56-that contain canonical Aß(1-40) and Aß(1-42), respectively, in AD mouse models.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!